Fundz

Artivion

Atlanta, United States · Biotechnology, Healthcare, Health Care

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vasc

Key facts

Headquarters
Atlanta, United States
Employees
1,600
Industries
Biotechnology, Healthcare, Health Care
Status
Public (AORT)
Website
artivion.com
LinkedIn
Company page

Recent activity at Artivion

  • : Artivion, Inc. Completes Acquisition of Endospan Ltd.
  • : Artivion to acquire Endospan for $335 million
  • : SEC 8-K (8.01): On May 18, 2026, Artivion, Inc. announced the completion of its acquisition of Endospan Ltd., an Israeli corporation specializing in innovative products for the treatment of aortic instability. This acquisition includes the Nexus™ product line, which is significant for Artivion's portfolio and market position in the medical device sector. The financial terms of the acquisition were not disclosed in the press release. This strategic move aims to enhance Artivion's product offerings and reinforce its commitment to delivering advanced solutions in cardiovascular care.
  • : SEC 8-K (8.01): On May 18, 2026, Artivion completed its acquisition of Endospan by exercising their option to purchase all outstanding securities of Endospan, as outlined in a Securities Purchase Option Agreement dated September 11, 2019. The total base purchase price was $175.0 million, to be paid entirely in cash, subject to adjustments for various factors including working capital and outstanding debt. The net purchase price after offsets was approximately $131.3 million, with $16.5 million set aside in an indemnity escrow fund. Additionally, Securityholders could earn contingent consideration of up to $200.0 million based on future performance metrics of Endospan's Nexus product. This acquisition represents a strategic expansion for Artivion in the medical technology field.
  • : SEC 8-K (5.07): At the Annual Meeting of Stockholders for Artivion, Inc. held on May 12, 2026, stockholders elected all nominated directors to serve until the next annual meeting. The meeting also involved a non-binding vote where stockholders approved the compensation for named executive officers, which included discussions and tables of their compensation. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent public accounting firm for the year ending December 31, 2026. This approval is significant as it sets the direction for the company's governance and future financial oversight.
  • : SEC 8-K (1.01): On May 7, 2026, Artivion, Inc. (formerly CryoLife, Inc.) entered into a Securities Purchase Option Agreement with Endospan Ltd., following Endospan's FDA approval of its Nexus™ product on April 2, 2026. Artivion paid $1.0 million for the option to purchase all outstanding securities or assets of Endospan, expiring 90 days after FDA approval. The agreement stipulates a base purchase price of $175.0 million, which Artivion plans to pay entirely in cash, with expected net costs after adjustments around $135.0 million. This move will ensure Artivion's control over future transactions involving Endospan, as its articles now provide Artivion with a veto share for significant corporate changes during the option period.
  • : CRYOLIFE INC
  • : CRYOLIFE INC

Artivion funding history

DateRoundAmount
Sep 2020Venture$20.0M
Jan 2016Venture$39.0M

Leadership

  • J. Mackin, Executive Officer, Director
  • Thomas Ackerman, Director
  • Daniel Bevevino, Director
  • Marna Borgstrom, Director
  • James Bullock, Director
  • Jeffrey Burbank, Director
  • Ronald McCall, Director
  • Harvey Morgan, Director
  • Jon Salveson, Director

Verified email and direct lines for Artivion’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Artivion files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Artivion in the news

Companies similar to Artivion

  • Edwards Lifesciences · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device
  • ShockWave Medical · Biotechnology, Healthcare, Health Care, Medical, Medical Device
  • Ascensia Diabetes Care · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • Cordica · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
  • Avanos Medical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device

About Artivion: questions and answers

What does Artivion do?

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vasc

Where is Artivion headquartered?

Artivion is headquartered in Atlanta, United States.

How many employees does Artivion have?

Artivion has about 1,600 employees.

Has Artivion raised funding?

Yes. Fundz has recorded 2 funding events for Artivion. The most recent, $20.0M, was in Sep 2020.

What is the latest news on Artivion?

On May 18, 2026, Artivion, Inc. Completes Acquisition of Endospan Ltd.

Is Artivion a public company?

Yes. Artivion is publicly traded under the ticker AORT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Artivion across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.